Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Physiomics Director Ian Bagnall acquired 1,111,111 ordinary shares at 0.45p per share through market purchases on 14 July 2026. - The transaction brings Mr Bagnall's total holding to 16,111,111 ordinary shares, representing approximately 3.55% of the company's issued share capital. - Physiomics is a mathematical modelling and data science company supporting drug development, with clients including Merck KGaA, Astellas, and Bicycle Therapeutics. - The company's proprietary Virtual Tumour technology has informed the development of over 140 commercial projects across more than 125 targets and drugs.
- The UK Nuclear Decommissioning Authority has signed a landmark agreement with Bicycle Therapeutics to produce tens of thousands of doses of advanced cancer therapies annually using reprocessed uranium from historic nuclear fuel processing. - The partnership will extract lead-212, a valuable medical isotope, from up to 400 tonnes of reprocessed uranium over 15 years to create targeted radiopharmaceuticals for hard-to-treat cancers including prostate and neuroendocrine tumors. - Bicycle Therapeutics, co-founded by Nobel Prize winner Sir Greg Winter, will use a novel extraction process developed by the UK National Nuclear Laboratory to deliver precision cancer treatments that destroy tumors while minimizing damage to healthy tissue. - The initiative represents a major breakthrough in repurposing nuclear materials for medical applications and strengthens the UK's position in nuclear-powered medical science innovation.
- Ankyra Therapeutics has appointed Sailaja Battula, PhD as Chief Scientific Officer, bringing over a decade of experience in immuno-oncology and drug discovery to the clinical-stage biotechnology company. - Dr. Battula previously held leadership roles at Immuneering Corporation and Bicycle Therapeutics, where she led pioneering work on bicyclic peptides as T cell agonists and tumor-targeting bispecifics. - The appointment comes as Ankyra advances its lead candidate Tolododekin alfa (ANK-101), an anchored drug conjugate that delivers IL-12 locally to tumors while avoiding systemic toxicity. - ANK-101 is currently being evaluated in first-in-human clinical trials for advanced solid tumors and non-mutated metastatic non-small cell lung cancer.
- Physiomics plc secured a new contract with GARDP Foundation to provide expert consultancy support for optimizing efficacy trial design in their Serious Bacterial Infections programme. - The three-month project beginning January 2026 marks Physiomics' expansion into infectious disease therapeutics and represents their third biometrics contract since launching the service line. - GARDP is a not-for-profit research organization focused on developing new antibiotic treatments while ensuring sustainable access to address global public health needs. - The contract award surpassed initial projections and demonstrates the promising contribution of Physiomics' biometrics service to the company's growth objectives.
- Bicycle toxin conjugates (BTCs) represent a rapidly evolving field in targeted oncology that combines the binding affinity of bicyclic peptides with cytotoxic chemotherapy activity. - Zelenectide pevedotin (BT8009) demonstrated striking efficacy in Phase 1/2 trials when combined with immune checkpoint inhibitors, showcasing the potential of upfront combination regimens. - The technology offers advantages over conventional antibody-drug conjugates through deep tissue penetration and decreased systemic exposure while maintaining therapeutic activity. - Regulatory bodies including the US FDA are showing increasing confidence in BTCs through ramp-up programs, indicating growing institutional acceptance of this novel therapeutic approach.
- Bicycle Therapeutics has postponed its expected dose selection and regulatory pathway update for zelenectide pevedotin in metastatic urothelial cancer from Q4 2025 to Q1 2026 as the company seeks feedback from multiple regulatory agencies. - The company continues advancing zelenectide pevedotin development across multiple NECTIN4-amplified cancers, with Phase 1/2 trials actively enrolling patients in breast cancer (Duravelo-3) and non-small cell lung cancer (Duravelo-4). - Bicycle Therapeutics maintains a strong financial position with $648.3 million in cash as of September 30, 2025, extending its runway into 2028 following strategic cost realignment efforts that reduced operational expenses by approximately 30%.
- Peptide drug conjugates represent a novel targeted therapy approach that combines disease-targeting peptides with small molecule drugs to deliver treatments directly to diseased tissues while minimizing systemic toxicity. - The global peptide drug conjugate market has experienced remarkable growth of over 300% absolute growth and 27% CAGR from 2018-2024, with market opportunities exceeding $1.4 billion. - Two peptide drug conjugates have received regulatory approval as of May 2025: Novartis's Lutathera for gastroenteropancreatic neuroendocrine tumors and Oncopeptides' Pepaxti for multiple myeloma. - More than 30 peptide drug conjugate candidates are currently advancing through various stages of clinical trials, primarily focused on oncology applications but expanding into neurodegenerative and inflammatory disorders.
• Bicycle Therapeutics' zelenectide pevedotin plus pembrolizumab shows a 65% overall response rate in cisplatin-ineligible metastatic urothelial cancer patients. • The Phase 1 trial data demonstrates a differentiated safety profile with primarily low-grade adverse events and no treatment withdrawals due to zelenectide. • Bicycle Therapeutics plans to initiate Phase 1/2 trials in 2025 for NECTIN4 gene-amplified breast and lung cancers, expanding zelenectide pevedotin's potential. • The company's financial runway extends into the second half of 2027, supporting ongoing clinical trials and strategic development of radiopharmaceuticals.
- Zelenectide pevedotin plus pembrolizumab achieved a 60% overall response rate in first-line metastatic urothelial cancer patients. - In breast cancer patients with NECTIN4 gene amplification, zelenectide pevedotin monotherapy demonstrated a 62.5% response rate. - NSCLC patients with NECTIN4 gene amplification showed a 40% response rate with zelenectide pevedotin monotherapy. - Bicycle Therapeutics plans Phase 1/2 trials in breast, lung, and other cancers, focusing on NECTIN4 gene amplification in 2025.
• Bicycle Therapeutics presented first human imaging data validating MT1-MMP as a novel target for cancer treatment at the EANM 2024 Congress. • The company demonstrated positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and optimized radioisotope delivery. • Bicycle Therapeutics has selected tumor antigen EphA2 as its second BRC target and signed a letter of intent with Eckert & Ziegler for radioisotope supply. • Bicycle's technology offers ideal properties for radioisotope delivery, including low molecular weight, high target selectivity, and rapid systemic clearance.
